Compare HRB & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HRB | PTCT |
|---|---|---|
| Founded | 1955 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 6.1B |
| IPO Year | N/A | 2013 |
| Metric | HRB | PTCT |
|---|---|---|
| Price | $39.75 | $75.53 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 2 | 17 |
| Target Price | $55.00 | ★ $73.76 |
| AVG Volume (30 Days) | ★ 1.4M | 1.2M |
| Earning Date | 02-03-2026 | 02-26-2026 |
| Dividend Yield | ★ 4.20% | N/A |
| EPS Growth | ★ 9.63 | N/A |
| EPS | 4.50 | ★ 8.94 |
| Revenue | ★ $3,770,736,000.00 | $1,779,150,000.00 |
| Revenue This Year | $4.28 | $129.80 |
| Revenue Next Year | $3.14 | N/A |
| P/E Ratio | $8.85 | ★ $8.42 |
| Revenue Growth | 4.15 | ★ 97.54 |
| 52 Week Low | $38.88 | $35.95 |
| 52 Week High | $64.62 | $87.50 |
| Indicator | HRB | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 30.86 | 48.43 |
| Support Level | $38.88 | $69.81 |
| Resistance Level | $45.24 | $77.87 |
| Average True Range (ATR) | 1.29 | 3.49 |
| MACD | -0.37 | -0.20 |
| Stochastic Oscillator | 13.99 | 55.06 |
H&R Block Inc provides income tax return preparation services, digital do-it-yourself tax solutions, and other services related to income tax preparation to the general public in the United States, Canada, and Australia. The company mainly prepares tax returns for customers within the United States through its company-owned offices, franchise locations, and online tax software. The vast majority of H&R Block's offices are located in the U.S. The company derives the majority of its total revenue from the U.S. assisted tax preparation fees. Revenue from franchise and product royalties and digital do-it-yourself tax solutions is also relatively.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.